Table 2. Virologic responses.

HCV RNA < LLOD	Patient (N = 273)
	n/N (%)	95% CI
During treatment
Week 4*	218/272 (80.2)	75.0–84.5
EOT*	272/272 (100)	98.6–100
After treatment
SVR12 (EP)†	264/273 (96.7)	93.9–98.3
SVR12 (PP)‡	264/271 (97.5)	94.8–98.8
Reason for non-SVR12, n
Relapse	7
Lost to follow-up	2
During treatment	1
After treatment	1

LLOD: lower limit of detection; EOT: end-of-treatment; EP: evaluate population; PP: per-protocol population; CI: confidence interval.

* One patient who expired at treatment week 3 did not have week 4 and EOT HCV RNA data.

^† Patients who received at least one dosage of treatment were included in the analysis.

^‡ Patients with non-virologic failure were excluded from the analysis.